From e6a47ab99c5dba06299f6eef685a5b506d5b3ed5 Mon Sep 17 00:00:00 2001
From: Vesa Oikonen <vesoik@utu.fi>
Date: Thu, 5 Jun 2025 13:59:53 +0300
Subject: [PATCH] added img title
---
content/acetate.html | 25 +++++--------------------
content/analysis_11c-pbr28.html | 2 +-
content/analysis_11c-pib.html | 2 +-
content/analysis_11c-pk11195.html | 2 +-
content/analysis_11c-smw139.html | 2 +-
content/analysis_11c-ucb-j.html | 2 +-
content/analysis_18f-ef5.html | 2 +-
content/analysis_18f-fbpa.html | 8 ++------
content/analysis_18f-fda.html | 6 ++++--
content/analysis_18f-fdg.html | 4 ++--
content/analysis_18f-fdopa.html | 4 ++--
content/analysis_18f-fgln.html | 2 +-
content/analysis_18f-fpa.html | 3 ++-
content/analysis_18f-fpatpp.html | 2 +-
content/analysis_18f-fpia.html | 3 ++-
content/analysis_18f-mfbg.html | 9 ++++++---
content/analysis_18f-psma-1007.html | 4 ++--
content/bnct.html | 2 +-
content/citrate.html | 2 +-
content/glucose.html | 2 +-
content/ketones.html | 17 +++++++++--------
content/lactate.html | 22 ++++++++++++----------
content/pyruvate.html | 2 +-
content/scfa.html | 18 +++++++++---------
content/stylesheets/style.css | 4 ++++
content/target_adenosine.html | 5 ++---
content/target_adrenergic_system.html | 12 ++++++------
content/target_ar.html | 6 +++---
content/target_dopamine.html | 4 ++--
content/target_sv2.html | 16 ++++++++--------
30 files changed, 94 insertions(+), 100 deletions(-)
diff --git a/content/acetate.html b/content/acetate.html
index 22b80d99..73f72c6f 100644
--- a/content/acetate.html
+++ b/content/acetate.html
@@ -36,7 +36,7 @@ monocarboxylate transporter and <a href="./target_aquaporins.html">aquaporins</a
across cell membranes.</p>
<p><a href="./pic/acetate-acetylCoA.svg"><img src="./pic/acetate-acetylCoA.svg"
- alt="acetate to acetyl-CoA conversion by ACH"
+ alt="acetate to acetyl-CoA conversion by ACH" title="acetate to acetyl-CoA conversion by ACH"
style="padding:6px 0px 0px 6px; width:350px; float:right;" /></a>
</p>
@@ -74,9 +74,9 @@ acetate (<a href="https://doi.org/10.1016/0969-8051(94)90178-3">Kihlberg et al.,
<div class="images">
<a href="./pic/1-11C-acetate.svg"><img src="./pic/1-11C-acetate.svg" height="80"
- alt="[1-11C]Acetate" style="padding:0px 10px 0px 0px;" /></a>
+ alt="[1-11C]Acetate" title="[1-11C]Acetate" style="padding:0px 10px 0px 0px;" /></a>
<a href="./pic/2-11C-acetate.svg"><img src="./pic/2-11C-acetate.svg" height="80"
- alt="[2-11C]Acetate" style="padding:0px 10px 0px 0px;" /></a>
+ alt="[2-11C]Acetate" title="[2-11C]Acetate" style="padding:0px 10px 0px 0px;" /></a>
<p>[1-<sup>11</sup>C]Acetate and [2-<sup>11</sup>C]acetate, labelled into C-1 and C-2 position,
respectively.</p>
</div>
@@ -116,7 +116,8 @@ of astrocytic metabolism in the brain
<h2><a name="18F"><sup>18</sup>F-labelled acetate</a></h2>
<p><a href="./pic/18F-fluoroacetate.svg"><img src="./pic/18F-fluoroacetate.svg"
- alt="18F-fluoroacetate" style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a>
+ alt="18F-fluoroacetate" title="18F-fluoroacetate"
+ style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a>
</p>
<p>The hydrogen atoms of the methyl group can be replaced with <sup>18</sup>F to produce
@@ -163,22 +164,6 @@ it with ethanol to increase lipophilicity. The resulting proradiotracer [<sup>18
the brain rapidly and was converted to TCA cycle metabolites
(<a href="https://doi.org/10.1016/j.nucmedbio.2008.11.006">Mori et al., 2009</a>).</p>
-<!-- Moved into its own page
-
-<p><a href="./pic/2-18F-fluoropropionate.svg"><img src="./pic/2-18F-fluoropropionate.svg"
- alt="18F-labelled propionate" style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a>
-</p>
-
-<h3><a name="FPA">2-[<sup>18</sup>F]fluoropropionate</a></h3>
-
-<p>2-[<sup>18</sup>F]fluoropropionate is another SCFA radiopharmaceutical that mimics acetate,
-and could be used in tumour imaging because of increased fatty acid synthesis
-(<a href="https://doi.org/10.2967/jnumed.109.064212">Pillarsetty et al., 2009</a>;
-<a href="https://doi.org/10.1177/1536012118821032">Zhao et al., 2019</a>;
-Zhang et al., <a href="https://doi.org/10.1007/s11307-019-01346-1">2019</a> and
-<a href="https://doi.org/10.1007/s11307-021-01608-x">2021</a>).</p>
--->
-
<br>
<h2>See also:</h2>
diff --git a/content/analysis_11c-pbr28.html b/content/analysis_11c-pbr28.html
index f05e5d6d..149b4b94 100644
--- a/content/analysis_11c-pbr28.html
+++ b/content/analysis_11c-pbr28.html
@@ -12,7 +12,7 @@ tags:
<h1>Quantification of [<sup>11</sup>C]PBR28 PET studies</h1>
-<p><a href="./pic/11C-PBR28.svg"><img src="./pic/11C-PBR28.svg" alt="11C-PBR28"
+<p><a href="./pic/11C-PBR28.svg"><img src="./pic/11C-PBR28.svg" alt="11C-PBR28" title="11C-PBR28"
style="padding:10px 0px 0px 10px; width:150px; float:right;" /></a>
</p>
diff --git a/content/analysis_11c-pib.html b/content/analysis_11c-pib.html
index fe78b3f4..fe13d387 100644
--- a/content/analysis_11c-pib.html
+++ b/content/analysis_11c-pib.html
@@ -13,7 +13,7 @@ tags:
<h1>Analysis of [<sup>11</sup>C]PIB PET data</h1>
<div>
-<p><a href="./pic/11C-PIB.svg"><img src="./pic/11C-PIB.svg" alt="11C-PIB"
+<p><a href="./pic/11C-PIB.svg"><img src="./pic/11C-PIB.svg" alt="11C-PIB" title="11C-PIB"
style="padding:10px 0px 0px 10px; width:200px; float:right;" /></a>
</p>
diff --git a/content/analysis_11c-pk11195.html b/content/analysis_11c-pk11195.html
index a92e0bf7..cb3e343b 100644
--- a/content/analysis_11c-pk11195.html
+++ b/content/analysis_11c-pk11195.html
@@ -14,7 +14,7 @@ tags:
<div>
-<p><a href="./pic/11C-PK11195.svg"><img src="./pic/11C-PK11195.svg" alt="11C-PK11195"
+<p><a href="./pic/11C-PK11195.svg"><img src="./pic/11C-PK11195.svg" alt="11C-PK11195" title="11C-PK11195"
style="padding:10px 0px 0px 10px; width:150px; float:right;" /></a>
</p>
diff --git a/content/analysis_11c-smw139.html b/content/analysis_11c-smw139.html
index c2f82906..828ab8d6 100644
--- a/content/analysis_11c-smw139.html
+++ b/content/analysis_11c-smw139.html
@@ -13,7 +13,7 @@ tags:
<p><a href="./pic/11C-SMW139.svg">
-<img src="./pic/11C-SMW139.svg" alt="[C-11]SMW139"
+<img src="./pic/11C-SMW139.svg" alt="[C-11]SMW139" title="[C-11]SMW139"
style="padding:10px 0px 0px 10px; width:200px; float:right;" />
</a></p>
diff --git a/content/analysis_11c-ucb-j.html b/content/analysis_11c-ucb-j.html
index 62234c3d..aa5af36a 100644
--- a/content/analysis_11c-ucb-j.html
+++ b/content/analysis_11c-ucb-j.html
@@ -13,7 +13,7 @@ tags:
<p><a name="fig1"></a>
<a href="./pic/(C-11)UCB-J.svg">
-<img src="./pic/(C-11)UCB-J.svg" alt="[C-11]UCB-J"
+<img src="./pic/(C-11)UCB-J.svg" alt="[C-11]UCB-J" title="[C-11]UCB-J"
style="padding:10px 0px 0px 10px; width:180px; float:right;" />
</a></p>
diff --git a/content/analysis_18f-ef5.html b/content/analysis_18f-ef5.html
index f85bf03d..f99e1b91 100644
--- a/content/analysis_18f-ef5.html
+++ b/content/analysis_18f-ef5.html
@@ -7,7 +7,7 @@ tags:
- Hypoxia
---
-<p><a href="./pic/18F-EF5.svg"><img src="./pic/18F-EF5.svg" alt="F-18 labelled EF5"
+<p><a href="./pic/18F-EF5.svg"><img src="./pic/18F-EF5.svg" alt="F-18 labelled EF5" title="F-18 labelled EF5"
style="padding:10px 0px 0px 10px; width:180px; float:right;" /></a></p>
<h1>[<sup>18</sup>F]EF5 PET</h1>
diff --git a/content/analysis_18f-fbpa.html b/content/analysis_18f-fbpa.html
index 62bf7970..d3bd9f6e 100644
--- a/content/analysis_18f-fbpa.html
+++ b/content/analysis_18f-fbpa.html
@@ -33,9 +33,9 @@ The effective dose from [<sup>18</sup>F]FBPA PET study is similar than that of
<figure style="border: 1px solid #000;">
<a href="./pic/L-BPA.svg">
- <img style="width:250px; margin: 0.5em;" src="./pic/L-BPA.svg" alt="L-BPA"></a>
+ <img style="width:250px; margin: 0.5em;" src="./pic/L-BPA.svg" alt="L-BPA" title="L-BPA"></a>
<a href="./pic/(F-18)FBPA.svg">
- <img style="width:250px; margin: 0.5em;" src="./pic/(F-18)FBPA.svg" alt="FBPA"></a>
+ <img style="width:250px; margin: 0.5em;" src="./pic/(F-18)FBPA.svg" alt="FBPA" title="FBPA"></a>
<figcaption style="margin: 0.5em;"><strong>L-BPA and [<sup>18</sup>F]FBPA</strong>
</figcaption>
</figure>
@@ -228,10 +228,6 @@ the <sup>10</sup>B in organs (normal tissues) by simply multiplying the relative
[<sup>18</sup>F]FBPA per g tissue by the therapeutic dose (g) of L-BPA, neglecting possible
saturation effects from the much higher mass of the L-BPA dose.</p>
-<--
-
--->
-
<br>
<h2>See also:</h2>
diff --git a/content/analysis_18f-fda.html b/content/analysis_18f-fda.html
index d40d56b6..c6674982 100644
--- a/content/analysis_18f-fda.html
+++ b/content/analysis_18f-fda.html
@@ -17,9 +17,11 @@ tags:
<figure style="border: 1px solid #000;">
<a href="./pic/norepinephrine.svg">
- <img style="width:220px; margin: 0.5em;" src="./pic/norepinephrine.svg" alt="Norepinephrine"></a>
+ <img style="width:220px; margin: 0.5em;" src="./pic/norepinephrine.svg"
+ alt="Norepinephrine" title="Norepinephrine"></a>
<a href="./pic/6-18F-FDA.svg">
- <img style="width:220px; margin: 0.5em;" src="./pic/6-18F-FDA.svg" alt="6-[F-18]-FDA"></a>
+ <img style="width:220px; margin: 0.5em;" src="./pic/6-18F-FDA.svg"
+ alt="6-[F-18]-FDA" title="6-[F-18]-FDA"></a>
<figcaption style="margin: 0.5em;">Norepinephrine (noradrenaline) and
6-[<sup>18</sup>F]fluorodopamine (6-[<sup>18</sup>F]FDA)
</figcaption>
diff --git a/content/analysis_18f-fdg.html b/content/analysis_18f-fdg.html
index 8dda7f62..5b68d5e2 100644
--- a/content/analysis_18f-fdg.html
+++ b/content/analysis_18f-fdg.html
@@ -19,8 +19,8 @@ tags:
<h1>Quantification of metabolic rate of glucose uptake with [<sup>18</sup>F]FDG</h1>
<p><a href="./pic/(F-18)fdg.svg">
-<img src="./pic/(F-18)fdg.svg" alt="2-[F-18]fluoro-2-deoxy-D-glucose"
- style="padding:10px 0px 0px 10px; width:200px; float:right;" />
+<img src="./pic/(F-18)fdg.svg" style="padding:10px 0px 0px 10px; width:200px; float:right;"
+ alt="2-[F-18]fluoro-2-deoxy-D-glucose" title="2-[F-18]fluoro-2-deoxy-D-glucose" />
</a></p>
<p>[<sup>18</sup>F]2-fluoro-2-deoxy-D-glucose ([<sup>18</sup>F]FDG) is a <a href="./glucose.html"
diff --git a/content/analysis_18f-fdopa.html b/content/analysis_18f-fdopa.html
index 3127535f..ef16ff25 100644
--- a/content/analysis_18f-fdopa.html
+++ b/content/analysis_18f-fdopa.html
@@ -32,9 +32,9 @@ and [<sup>18</sup>F]FPDOPA
<figure style="border: 1px solid #000;">
<a href="./pic/L-DOPA.svg">
- <img style="width:250px; margin: 0.5em;" src="./pic/L-DOPA.svg" alt="L-DOPA"></a>
+ <img style="width:250px; margin: 0.5em;" src="./pic/L-DOPA.svg" alt="L-DOPA" title="L-DOPA"></a>
<a href="./pic/6-(F-18)FDOPA.svg">
- <img style="width:250px; margin: 0.5em;" src="./pic/6-(F-18)FDOPA.svg" alt="FDOPA"></a>
+ <img style="width:250px; margin: 0.5em;" src="./pic/6-(F-18)FDOPA.svg" alt="FDOPA" title="FDOPA"></a>
<figcaption style="margin: 0.5em;"><strong>L-DOPA and 6-[<sup>18</sup>F]FDOPA</strong>
</figcaption>
</figure>
diff --git a/content/analysis_18f-fgln.html b/content/analysis_18f-fgln.html
index f7004b9c..af2fb75f 100644
--- a/content/analysis_18f-fgln.html
+++ b/content/analysis_18f-fgln.html
@@ -12,7 +12,7 @@ tags:
<h1>(2<em>S</em>,4<em>R</em>)-4-[<sup>18</sup>F]fluoroglutamine</h1>
<div><a href="./pic/2S4R-4-18F-FGln.png"><img src="./pic/2S4R-4-18F-FGln.png"
- alt="(2S,4R)-4-[18F]fluoroglutamine"
+ alt="(2S,4R)-4-[18F]fluoroglutamine" title="(2S,4R)-4-[18F]fluoroglutamine"
style="padding:10px 0px 0px 10px; width:200px; float:right;" /></a></div>
<p><a href="./glutamine.html">L-Glutamine</a> (Gln) has many important functions in
diff --git a/content/analysis_18f-fpa.html b/content/analysis_18f-fpa.html
index ccf4d6e1..dad0b116 100644
--- a/content/analysis_18f-fpa.html
+++ b/content/analysis_18f-fpa.html
@@ -13,7 +13,8 @@ tags:
<p><a href="./pic/2-18F-fluoropropionate.svg"><img src="./pic/2-18F-fluoropropionate.svg"
- alt="18F-labelled propionate" style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a>
+ alt="18F-labelled propionate" title="18F-labelled propionate"
+ style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a>
</p>
<p>2-[<sup>18</sup>F]fluoropropionate (2-[<sup>18</sup>F]fluoropropionic acid, [<sup>18</sup>F]FPA)
diff --git a/content/analysis_18f-fpatpp.html b/content/analysis_18f-fpatpp.html
index 843f0a57..312ec785 100644
--- a/content/analysis_18f-fpatpp.html
+++ b/content/analysis_18f-fpatpp.html
@@ -8,7 +8,7 @@ tags:
- Cannabinoids
---
-<div><a href="./pic/18F-FPATPP.png"><img src="./pic/18F-FPATPP.png" alt="[18F]FPATPP"
+<div><a href="./pic/18F-FPATPP.png"><img src="./pic/18F-FPATPP.png" alt="[18F]FPATPP" title="[18F]FPATPP"
style="padding:10px 0px 0px 10px; width:260px; float:right;" /></a></div>
<h1>[<sup>18</sup>F]FPATPP PET</h1>
diff --git a/content/analysis_18f-fpia.html b/content/analysis_18f-fpia.html
index ee9c7d43..51fe3672 100644
--- a/content/analysis_18f-fpia.html
+++ b/content/analysis_18f-fpia.html
@@ -11,7 +11,8 @@ tags:
<h1>[<sup>18</sup>F]FPIA PET</h1>
<p><a href="./pic/18F-FPIA.svg"><img src="./pic/18F-FPIA.svg"
- alt="18F-labelled pivalate" style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a>
+ alt="18F-labelled pivalate" title="18F-labelled pivalate"
+ style="padding:6px 0px 0px 6px; width:100px; float:right;" /></a>
</p>
<p>[<sup>18</sup>F]Fluoro-pivalic acid ([<sup>18</sup>F]FPIA) is based on a non-natural
diff --git a/content/analysis_18f-mfbg.html b/content/analysis_18f-mfbg.html
index 55a8f3a0..4c7c6ced 100644
--- a/content/analysis_18f-mfbg.html
+++ b/content/analysis_18f-mfbg.html
@@ -33,11 +33,14 @@ is safer, allows same-day imaging, and better image quality than what is possibl
<figure style="border: 1px solid #000;">
<a href="./pic/norepinephrine.svg">
- <img style="width:160px; margin: 0.5em;" src="./pic/norepinephrine.svg" alt="Noradrenaline"></a>
+ <img style="width:160px; margin: 0.5em;" src="./pic/norepinephrine.svg"
+ alt="Noradrenaline" title="Noradrenaline"></a>
<a href="./pic/123I-MIBG.svg">
- <img style="width:200px; margin: 0.5em;" src="./pic/123I-MIBG.svg" alt="[I-123]MIBG"></a>
+ <img style="width:200px; margin: 0.5em;" src="./pic/123I-MIBG.svg"
+ alt="[I-123]MIBG" title="[I-123]MIBG"></a>
<a href="./pic/18F-MFBG.svg">
- <img style="width:200px; margin: 0.5em;" src="./pic/18F-MFBG.svg" alt="[F-18]MFBG"></a>
+ <img style="width:200px; margin: 0.5em;" src="./pic/18F-MFBG.svg"
+ alt="[F-18]MFBG" title="[F-18]MFBG"></a>
<figcaption style="margin: 0.5em;">Noradrenaline, [<sup>123</sup>I]MIBG, and [<sup>18</sup>F]MFBG
</figcaption>
</figure>
diff --git a/content/analysis_18f-psma-1007.html b/content/analysis_18f-psma-1007.html
index b5916a48..34352c83 100644
--- a/content/analysis_18f-psma-1007.html
+++ b/content/analysis_18f-psma-1007.html
@@ -9,7 +9,8 @@ tags:
---
-<div><a href="./pic/18F-PSMA-1007.svg"><img src="./pic/18F-PSMA-1007.svg" alt="[18F]PSMA-1007"
+<div><a href="./pic/18F-PSMA-1007.svg"><img src="./pic/18F-PSMA-1007.svg"
+ alt="[18F]PSMA-1007" title="[18F]PSMA-1007"
style="padding:10px 0px 0px 10px; width:300px; float:right;" /></a></div>
@@ -117,7 +118,6 @@ was 0.05±0.02 min<sup>-1</sup> in prostate cancer lesions;
0.09±0.08, 0.15±0.08, and 0.04±0.02 in bone metastases;
median <em>k<sub>3</sub></em> was 35-fold higher than <em>k<sub>4</sub></em> in prostate cancer
lesions (<a href="https://doi.org/10.1007/s00259-019-04569-0">Sachpekidis et al., 2020</a>).
-
</p>
<h3>Mass effect</h3>
diff --git a/content/bnct.html b/content/bnct.html
index 67cfaf47..6198769f 100644
--- a/content/bnct.html
+++ b/content/bnct.html
@@ -47,7 +47,7 @@ this highly useful technique. Accelerator-based neutron sources are being develo
<div>
<a href="./pic/L-BPA.svg">
-<img src="./pic/L-BPA.svg" alt="L-BPA"
+<img src="./pic/L-BPA.svg" alt="L-BPA" title="L-BPA"
style="padding:8px 0px 0px 8px; width:180px; float:right;" /></a>
<p>Numerous boron carriers have been developed and studied, and two,
diff --git a/content/citrate.html b/content/citrate.html
index 840bd239..8c8040a7 100644
--- a/content/citrate.html
+++ b/content/citrate.html
@@ -10,7 +10,7 @@ tags:
<p>
<a href="./pic/citrate.svg">
-<img src="./pic/citrate.svg" alt="citrate ion"
+<img src="./pic/citrate.svg" alt="citrate ion" title="citrate ion"
style="padding:10px 0px 0px 10px; width:180px; float:right;" />
</a>
</p>
diff --git a/content/glucose.html b/content/glucose.html
index 29615b21..777922fb 100644
--- a/content/glucose.html
+++ b/content/glucose.html
@@ -16,7 +16,7 @@ tags:
<p>
<a href="./pic/D-glucose.svg">
-<img src="./pic/D-glucose.svg" alt="D-Glucose"
+<img src="./pic/D-glucose.svg" alt="D-Glucose" title="D-Glucose"
style="padding:10px 0px 0px 10px; width:200px; float:right;" />
</a>
</p>
diff --git a/content/ketones.html b/content/ketones.html
index 596fbf05..5c717ef0 100644
--- a/content/ketones.html
+++ b/content/ketones.html
@@ -12,21 +12,21 @@ tags:
<p>Ketone bodies include acetoacetate (AcAc), D-β-hydroxybutyrate (β-HB, BHB), and
acetone. L-β-hydroxybutyrate is not used in energy metabolism but excreted in the urine.<p>
-<table class="borderless" style="width: 95%;">
+<table class="borderless" id="borderlesstable" style="width: 95%;">
<tr>
<td><figure style="border: 0px;">
<a href="./pic/acetone.svg">
- <img style="margin: 0.5em;" src="./pic/acetone.svg" alt="Acetone"></a>
+ <img style="margin: 0.5em;" src="./pic/acetone.svg" alt="Acetone" title="Acetone"></a>
<figcaption style="margin: 0.5em;">Acetone</figcaption>
</figure></td>
<td><figure style="border: 0px;">
<a href="./pic/acac.svg">
- <img style="margin: 0.5em;" src="./pic/acac.svg" alt="Acetoacetate"></a>
+ <img style="margin: 0.5em;" src="./pic/acac.svg" alt="Acetoacetate" title="Acetoacetate"></a>
<figcaption style="margin: 0.5em;">Acetoacetate (AcAc)</figcaption>
</figure></td>
<td><figure style="border: 0px;">
<a href="./pic/bhb.svg">
- <img style="margin: 0.5em;" src="./pic/bhb.svg" alt="beta-hydroxybutyrate"></a>
+ <img style="margin: 0.5em;" src="./pic/bhb.svg" alt="beta-hydroxybutyrate" title="beta-hydroxybutyrate"></a>
<figcaption style="margin: 0.5em;">β-hydroxybutyrate (β-HB)</figcaption>
</figure></td>
</tr>
@@ -84,23 +84,24 @@ and β-hydroxybutyrate with <sup>11</sup>C and <sup>18</sup>F, giving
(3<em>S</em>)-4-[<sup>18</sup>F]fluoro-3-hydroxybutyric acid ([<sup>18</sup>F]FBHB).
Ketones have also been labelled with <sup>13</sup>C for NMR studies.</p>
-<table class="borderless" style="width: 95%;">
+<table class="borderless" id="borderlesstable" style="width: 95%;">
<tr>
<td><figure style="border: 0px;">
<a href="./pic/1-11C-acetoacetate.svg">
- <img style="margin: 0.5em;" src="./pic/1-11C-acetoacetate.svg" alt="[1-11C]acetoacetate"></a>
+ <img style="margin: 0.5em;" src="./pic/1-11C-acetoacetate.svg"
+ alt="[1-11C]acetoacetate" title="[1-11C]acetoacetate"></a>
<figcaption style="margin: 0.5em;">[<sup>11</sup>C]AcAc</figcaption>
</figure></td>
<td><figure style="border: 0px;">
<a href="./pic/beta-1-11C-hydroxybutyrate.svg">
<img style="margin: 0.5em;" src="./pic/beta-1-11C-hydroxybutyrate.svg"
- alt="beta-[1-11C]-hydroxybutyrate"></a>
+ alt="beta-[1-11C]-hydroxybutyrate" title="beta-[1-11C]-hydroxybutyrate"></a>
<figcaption style="margin: 0.5em;">[<sup>11</sup>C]β-HB</figcaption>
</figure></td>
<td><figure style="border: 0px;">
<a href="./pic/4-18F-3-hydroxybutyrate.svg">
<img style="margin: 0.5em;" src="./pic/4-18F-3-hydroxybutyrate.svg"
- alt="4-[18F]-3-hydroxybutyrate"></a>
+ alt="4-[18F]-3-hydroxybutyrate" title="4-[18F]-3-hydroxybutyrate"></a>
<figcaption style="margin: 0.5em;">[<sup>18</sup>F]FBHB</figcaption>
</figure></td>
</tr>
diff --git a/content/lactate.html b/content/lactate.html
index 16d76ff8..e7e6ec09 100644
--- a/content/lactate.html
+++ b/content/lactate.html
@@ -47,7 +47,7 @@ mediate metabolic signals through the nervous tissue
present at physiological pH.</p>
<p><a href="./pic/lactate-pyruvate.svg"><img src="./pic/lactate-pyruvate.svg"
- alt="lactate-pyruvate conversion by LDH"
+ alt="lactate-pyruvate conversion by LDH" title="lactate-pyruvate conversion by LDH"
style="padding:6px 0px 0px 6px; width:320px; float:right;" /></a>
</p>
@@ -61,7 +61,7 @@ L-lactate can be concerted back to glucose via gluconeogenesis.
Kidneys maintain pyruvate/lactate ratio in circulation by converting lactate into pyruvate.</p>
<p><a href="./pic/pyruvate-acetylCoA.svg"><img src="./pic/pyruvate-acetylCoA.svg"
- alt="pyruvate to acetyl-CoA conversion by PDH"
+ alt="pyruvate to acetyl-CoA conversion by PDH" title="pyruvate to acetyl-CoA conversion by PDH"
style="padding:6px 0px 0px 6px; width:350px; float:right;" /></a>
</p>
@@ -238,14 +238,17 @@ the TCA cycle.</p>
<div class="images">
<a href="./pic/L-1-11C-lactate.svg">
-<img src="./pic/L-1-11C-lactate.svg" alt="[C-11]Lactate, labeled into C-1 position"
- style="padding:0px 20px 0px 0px;" /></a>
+<img src="./pic/L-1-11C-lactate.svg" style="padding:0px 20px 0px 0px;"
+ alt="[C-11]Lactate, labeled into C-1 position"
+ title="[C-11]Lactate, labeled into C-1 position" /></a>
<a href="./pic/L-3-11C-lactate.svg">
-<img src="./pic/L-3-11C-lactate.svg" alt="[C-11]Lactate, labeled into C-3 position"
- style="padding:0px 20px 0px 0px;" /></a>
+<img src="./pic/L-3-11C-lactate.svg" style="padding:0px 20px 0px 0px;"
+ alt="[C-11]Lactate, labeled into C-3 position"
+ title="[C-11]Lactate, labeled into C-3 position" /></a>
<a href="./pic/18F-S-FL.svg">
-<img src="./pic/18F-S-FL.svg" alt="[F-18]Lactate, labeled into C-3 position"
- style="padding:0px 20px 0px 0px;" /></a>
+<img src="./pic/18F-S-FL.svg" style="padding:0px 20px 0px 0px;"
+ alt="[F-18]Lactate, labeled into C-3 position"
+ title="[F-18]Lactate, labeled into C-3 position" /></a>
<p><strong>Figure 1.</strong> L-1-[<sup>11</sup>C]lactate and L-3-[<sup>11</sup>C]lactate, labelled
into C-1 and C-3 position, respectively; [<sup>18</sup>F]<em>S</em>-fluorolactate, labelled into C-3
position.</p>
@@ -345,8 +348,7 @@ cells <em>in vitro</em> and tumours <em>in vivo</em>
(<a href="https://doi.org/10.18632/oncotarget.14705">Van Hée et al., 2017</a>).
Low levels of radioactivity in bone after 1 h of <sup>18</sup>F]-<em>S</em>-FL administration
indicates a low level of defluorination of the radiotracer
-(<a href="https://doi.org/10.3390/cancers12061703">Braga et al., 2020</a>).
-</p>
+(<a href="https://doi.org/10.3390/cancers12061703">Braga et al., 2020</a>).</p>
<br>
diff --git a/content/pyruvate.html b/content/pyruvate.html
index 08d87ab2..d37ee166 100644
--- a/content/pyruvate.html
+++ b/content/pyruvate.html
@@ -28,7 +28,7 @@ L-lactate dehydrogenase (LDH).</p>
<p><a href="./pic/pyruvate-acetylCoA.svg"><img src="./pic/pyruvate-acetylCoA.svg"
- alt="pyruvate to acetyl-CoA conversion by PDH"
+ alt="pyruvate to acetyl-CoA conversion by PDH" title="pyruvate to acetyl-CoA conversion by PDH"
style="padding:6px 0px 0px 6px; width:350px; float:right;" /></a>
</p>
diff --git a/content/scfa.html b/content/scfa.html
index 88e1c21b..343fd888 100644
--- a/content/scfa.html
+++ b/content/scfa.html
@@ -1,7 +1,7 @@
---
title: SCFAs
author: Vesa Oikonen
-updated_at: 2025-06-04
+updated_at: 2025-06-05
created_at: 2025-06-02
tags:
- Fatty acids
@@ -29,14 +29,14 @@ Zhang et al., <a href="https://doi.org/10.1007/s11307-019-01346-1">2019</a> and
<a href="https://doi.org/10.1007/s11307-021-01608-x">2021</a>).</p>
<figure style="border: 1px solid #000;">
- <img style="margin: 0.5em;" src="./pic/scfa_acetate.svg" alt="Acetate (ethanoate)">
- <img style="margin: 0.5em;" src="./pic/scfa_propionate.svg" alt="Propionate (propanoate)">
- <img style="margin: 0.5em;" src="./pic/scfa_butyrate.svg" alt="Butyrate (butanoate)">
- <img style="margin: 0.5em;" src="./pic/scfa_valerate.svg" alt="Valerate (pentanoate)">
- <img style="margin: 0.5em;" src="./pic/scfa_isobutyrate.svg" alt="Isobutyrate (2-methylpropanoate)">
- <img style="margin: 0.5em;" src="./pic/scfa_2-methylbutyrate.svg" alt="2-Methylbutyrate (2-methylbutanoate)">
- <img style="margin: 0.5em;" src="./pic/scfa_isovalerate.svg" alt="Isovalerate (3-methylbutanoate)">
- <img style="margin: 0.5em;" src="./pic/scfa_pivalate.svg" alt="Pivalate (trimethylacetate)">
+ <img style="margin: 0.5em;" src="./pic/scfa_acetate.svg" alt="Acetate (ethanoate)" title="Acetate (ethanoate)">
+ <img style="margin: 0.5em;" src="./pic/scfa_propionate.svg" alt="Propionate (propanoate)" title="Propionate (propanoate)">
+ <img style="margin: 0.5em;" src="./pic/scfa_butyrate.svg" alt="Butyrate (butanoate)" title="Butyrate (butanoate)">
+ <img style="margin: 0.5em;" src="./pic/scfa_valerate.svg" alt="Valerate (pentanoate)" title="Valerate (pentanoate)">
+ <img style="margin: 0.5em;" src="./pic/scfa_isobutyrate.svg" alt="Isobutyrate (2-methylpropanoate)" title="Isobutyrate (2-methylpropanoate)">
+ <img style="margin: 0.5em;" src="./pic/scfa_2-methylbutyrate.svg" alt="2-Methylbutyrate (2-methylbutanoate)" title="2-Methylbutyrate (2-methylbutanoate)">
+ <img style="margin: 0.5em;" src="./pic/scfa_isovalerate.svg" alt="Isovalerate (3-methylbutanoate)" title="Isovalerate (3-methylbutanoate)">
+ <img style="margin: 0.5em;" src="./pic/scfa_pivalate.svg" alt="Pivalate (trimethylacetate)" title="Pivalate (trimethylacetate)">
</figure>
<p>SCFAs include also a non-natural substrate pivalate (trimethylacetate), which cannot be oxidized
diff --git a/content/stylesheets/style.css b/content/stylesheets/style.css
index 5d145c21..49c74f06 100644
--- a/content/stylesheets/style.css
+++ b/content/stylesheets/style.css
@@ -262,6 +262,10 @@ table.borderless th, tr, td {
border-collapse: collapse;
border: 0px;
}
+#borderlesstable {
+ border-collapse: collapse;
+ border: 0;
+}
table.mask, tr, td {
border: 1px solid black;
diff --git a/content/target_adenosine.html b/content/target_adenosine.html
index 7eaeafa5..2a94b242 100644
--- a/content/target_adenosine.html
+++ b/content/target_adenosine.html
@@ -19,7 +19,7 @@ tags:
<div>
<a href="./pic/adenosine.svg">
-<img src="./pic/adenosine.svg" alt="Adenosine"
+<img src="./pic/adenosine.svg" alt="Adenosine" title="Adenosine"
style="padding:10px 0px 0px 10px; width:160px; float:right;" />
</a>
@@ -103,8 +103,7 @@ radiopharmaceuticals for A<sub>1</sub>R and A<sub>2A</sub>R are routinely used i
Agonists, including endogenous agonist adenosine, lead to the activation of all AR subtypes, and
subsequent regulation by desensitization and trafficking
(<a href="https://doi.org/10.1016/j.bbamem.2010.06.007">Mundell and Kelly, 2011</a>).
-In addition to AR agonists and antagonists, also allosteric modulators have been introduced.
-</p>
+In addition to AR agonists and antagonists, also allosteric modulators have been introduced.</p>
<h3><a name="a1r">A<sub>1</sub>R</a></h3>
diff --git a/content/target_adrenergic_system.html b/content/target_adrenergic_system.html
index 1d0345dd..3e6cdf48 100644
--- a/content/target_adrenergic_system.html
+++ b/content/target_adrenergic_system.html
@@ -25,10 +25,10 @@ as neurohormones from <a href="./organ_adrenal_gland.html">adrenal medulla</a>.
<div class="images">
<a href="./pic/epinephrine.svg">
-<img src="./pic/epinephrine.svg" alt="Epinephrine/Adrenaline"
+<img src="./pic/epinephrine.svg" alt="Epinephrine/Adrenaline" title="Epinephrine/Adrenaline"
style="padding:0px 20px 0px 0px;" /></a>
<a href="./pic/norepinephrine.svg">
-<img src="./pic/norepinephrine.svg" alt="Norepinephrine/Noradrenaline"
+<img src="./pic/norepinephrine.svg" alt="Norepinephrine/Noradrenaline" title="Norepinephrine/Noradrenaline"
style="padding:0px 20px 0px 0px;" /></a>
<p>Adrenaline (epinephrine) and noradrenaline (norepinephrine).</p>
</div>
@@ -69,24 +69,24 @@ Noradrenaline is metabolized by MAO-A and MAO-B, and COMT.</p>
<tr>
<td><figure style="border: 0px;">
<a href="./pic/L-phenylalanine.svg">
- <img style="margin: 0.5em;" src="./pic/L-phenylalanine.svg" alt="L-Phenylalanine"></a>
+ <img style="margin: 0.5em;" src="./pic/L-phenylalanine.svg" alt="L-Phenylalanine" title="L-Phenylalanine"></a>
<figcaption style="margin: 0.5em;">L-Phenylalanine</figcaption>
</figure></td>
<td><figure style="border: 0px;">
<a href="./pic/L-tyrosine.svg">
- <img style="margin: 0.5em;" src="./pic/L-tyrosine.svg" alt="L-Tyrosine"></a>
+ <img style="margin: 0.5em;" src="./pic/L-tyrosine.svg" alt="L-Tyrosine" title="L-Tyrosine"></a>
<figcaption style="margin: 0.5em;">L-Tyrosine</figcaption>
</figure></td>
</tr>
<tr>
<td><figure style="border: 0px;">
<a href="./pic/L-DOPA.svg">
- <img style="margin: 0.5em;" src="./pic/L-DOPA.svg" alt="L-DOPA"></a>
+ <img style="margin: 0.5em;" src="./pic/L-DOPA.svg" alt="L-DOPA" title="L-DOPA"></a>
<figcaption style="margin: 0.5em;">L-DOPA</figcaption>
</figure></td>
<td><figure style="border: 0px;">
<a href="./pic/dopamine.svg">
- <img style="margin: 0.5em;" src="./pic/dopamine.svg" alt="Dopamine"></a>
+ <img style="margin: 0.5em;" src="./pic/dopamine.svg" alt="Dopamine" title="Dopamine"></a>
<figcaption style="margin: 0.5em;">Dopamine</figcaption>
</figure></td>
</tr>
diff --git a/content/target_ar.html b/content/target_ar.html
index 4f661b01..e0fea0ae 100644
--- a/content/target_ar.html
+++ b/content/target_ar.html
@@ -13,7 +13,7 @@ tags:
<figure style="float:right;">
<a href="./pic/testosterone.svg">
- <img src="./pic/testosterone.svg" alt="Testosterone" style="width:140px;" /></a>
+ <img src="./pic/testosterone.svg" alt="Testosterone" title="Testosterone" style="width:140px;" /></a>
<figcaption style="margin: 0.5em; font-size: 75%;">Testosterone</figcaption>
</figure>
@@ -45,7 +45,7 @@ SHBG binding also helps in hormone transport into target cells through membrane
(DHEA), further to androstenedione, and to testosterone
(<a href="https://doi.org/10.1016/j.mednuc.2015.02.005">Lefebvre-Lacœuille et al., 2015</a>).
Testosterone is produced primarily in testicular Leydig cells in men, while in women precursors are
-biosynthesised in the <a href="./organ_adrenal_gland.html">adrenal cortex</a> and
+biosynthesized in the <a href="./organ_adrenal_gland.html">adrenal cortex</a> and
<a href="./organ_ovary.html">ovaries</a> and converted into testosterone in peripheral tissues.
</p>
@@ -86,7 +86,7 @@ AR radioligands, such as [<sup>18</sup>F]FDHT
<figure style="float:right;">
<a href="./pic/18F-FDHT.svg">
- <img src="./pic/18F-FDHT.svg" alt="[F-18]FDHT" style="width:170px;" /></a>
+ <img src="./pic/18F-FDHT.svg" alt="[F-18]FDHT" title="[F-18]FDHT" style="width:170px;" /></a>
</figure>
<p>16β-[<sup>18</sup>F]fluoro-5α-dihydrotestosterone ([<sup>18</sup>F]FDHT)
diff --git a/content/target_dopamine.html b/content/target_dopamine.html
index 6c113b80..a72b9633 100644
--- a/content/target_dopamine.html
+++ b/content/target_dopamine.html
@@ -90,9 +90,9 @@ Dopamine is packaged into synaptic vesicles by vesicular monoamine transporter 2
<figure style="border: 1px solid #000;">
<a href="./pic/dopamine.svg">
- <img style="width:200px; margin: 0.5em;" src="./pic/dopamine.svg" alt="Dopamine"></a>
+ <img style="width:200px; margin: 0.5em;" src="./pic/dopamine.svg" alt="Dopamine" title="Dopamine"></a>
<a href="./pic/L-DOPA.svg">
- <img style="width:250px; margin: 0.5em;" src="./pic/L-DOPA.svg" alt="L-DOPA"></a>
+ <img style="width:250px; margin: 0.5em;" src="./pic/L-DOPA.svg" alt="L-DOPA" title="L-DOPA"></a>
<figcaption style="margin: 0.5em;">Dopamine and L-DOPA</figcaption>
</figure>
diff --git a/content/target_sv2.html b/content/target_sv2.html
index 8acb4dcd..9c224dd5 100644
--- a/content/target_sv2.html
+++ b/content/target_sv2.html
@@ -92,12 +92,12 @@ levetiracetam. SV2A modulates epileptogenesis via GABAergic, but not glutamaterg
<tr>
<td><figure style="border: 0px;">
<a href="./pic/levetiracetam.svg">
- <img style="margin: 0.5em;" src="./pic/levetiracetam.svg" alt="Levetiracetam"></a>
+ <img style="margin: 0.5em;" src="./pic/levetiracetam.svg" alt="Levetiracetam" title="Levetiracetam"></a>
<figcaption style="margin: 0.5em;">Levetiracetam</figcaption>
</figure></td>
<td><figure style="border: 0px;">
<a href="./pic/brivaracetam.svg">
- <img style="margin: 0.5em;" src="./pic/brivaracetam.svg" alt="Brivaracetam"></a>
+ <img style="margin: 0.5em;" src="./pic/brivaracetam.svg" alt="Brivaracetam" title="Brivaracetam"></a>
<figcaption style="margin: 0.5em;">Brivaracetam</figcaption>
</figure></td>
</tr>
@@ -160,24 +160,24 @@ The specific binding of [<sup>18</sup>F]UCB-H is relatively low, hampering quant
<tr>
<td><figure style="border: 0px;">
<a href="./pic/UCB-J.svg">
- <img style="margin: 0.5em;" src="./pic/UCB-J.svg" alt="UCB-J"></a>
+ <img style="margin: 0.5em;" src="./pic/UCB-J.svg" alt="UCB-J" title="UCB-J"></a>
<figcaption style="margin: 0.5em;">UCB-J</figcaption>
</figure></td>
<td><figure style="border: 0px;">
<a href="./pic/UCB-H.svg">
- <img style="margin: 0.5em;" src="./pic/UCB-H.svg" alt="UCB-H"></a>
+ <img style="margin: 0.5em;" src="./pic/UCB-H.svg" alt="UCB-H" title="UCB-H"></a>
<figcaption style="margin: 0.5em;">UCB-H</figcaption>
</figure></td>
</tr>
<tr>
<td><figure style="border: 0px;">
<a href="./pic/SynVesT-1.svg">
- <img style="margin: 0.5em;" src="./pic/SynVesT-1.svg" alt="SynVesT-1"></a>
+ <img style="margin: 0.5em;" src="./pic/SynVesT-1.svg" alt="SynVesT-1" title="SynVesT-1"></a>
<figcaption style="margin: 0.5em;">SynVesT-1, MNI-1126, SDM-8</figcaption>
</figure></td>
<td><figure style="border: 0px;">
<a href="./pic/SynVesT-2.svg">
- <img style="margin: 0.5em;" src="./pic/SynVesT-2.svg" alt="SynVesT-2"></a>
+ <img style="margin: 0.5em;" src="./pic/SynVesT-2.svg" alt="SynVesT-2" title="SynVesT-2"></a>
<figcaption style="margin: 0.5em;">SynVesT-2, SDM-2</figcaption>
</figure></td>
</tr>
@@ -190,11 +190,11 @@ radioligands (<a href="https://doi.org/10.1007/s00259-021-05597-5">Zheng et al.,
<table class="borderless" style="width: 95%;">
<tr>
<td><figure style="border: 0px;">
- <a href="./pic/UCB-A.svg"><img style="margin: 0.5em;" src="./pic/UCB-A.svg" alt="UCB-A"></a>
+ <a href="./pic/UCB-A.svg"><img style="margin: 0.5em;" src="./pic/UCB-A.svg" alt="UCB-A" title="UCB-A"></a>
<figcaption style="margin: 0.5em;">UCB-A</figcaption>
</figure></td>
<td><figure style="border: 0px;">
- <a href="./pic/SDM-16.svg"><img style="margin: 0.5em;" src="./pic/SDM-16.svg" alt="SDM-16"></a>
+ <a href="./pic/SDM-16.svg"><img style="margin: 0.5em;" src="./pic/SDM-16.svg" alt="SDM-16" title="SDM-16"></a>
<figcaption style="margin: 0.5em;">SDM-16</figcaption>
</figure></td>
</tr>
--
GitLab